Pfizer Drug Could Be First Of Wave Of Nucleic Medicines Approved In Japan
This article was originally published in PharmAsia News
Biotechnology methods of finding new ways to fight diseases are part of a growing business move in Japan as major drug makers take a nucleic-acid approach to drugs. The new treatment strategy is expected to reach a milestone when Pfizer receives approval from the Health Ministry for its age-related macular degeneration drug Macugen (pegaptanib), probably later this month. The drug relies on aptamers, synthetic molecules of a certain shape to bind better with targeted proteins. The head of Ribomic, a Tokyo bioventure, said approval of Macugen is likely to spur development in Japan. (Click here for more - a subscription may be required
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.